Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Molecular Insight Pharmaceuticals, a biopharmaceutical company, has announced that John Babich, president and chief scientific officer of the company, will replace David Barlow as the company's interim CEO and chairman of the board, effective immediately.
Subscribe to our email newsletter
Mr Barlow will continue to serve out his term as a member of the company’s board of directors. The company had begun a search to identify a permanent CEO.
Molecular Insight Pharmaceuticals’s board said: “The board determined that new leadership at the chair and CEO level was necessary for the company to execute on its strategic plan.
“We believe that the company is well-positioned with the right infrastructure and strong product candidates in the FDA approval process to exploit its market opportunities. We thank David for his contributions and wish him all the best in his future endeavors.”